stockrow
Friday 6 November 2026
Export STIM’s income statement to Excel — free account
Neuronetics, Inc.
STIM Healthcare Medical Devices
Neuronetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $149.2 million, up 99.2% from fiscal 2024.
- Revenue
- +12.5%
- EPS
- +84.6%
- Free cash flow
- +237.7%
- Total debt
- −5.97%
Quarter to September 2026, against a year earlier
2.17
0.26
−10.70%
Follow STIM
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 4 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.61 | 0.67 | 0.61 | 1.13 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
100.23 | (10.71) | (94.31) | 145.55 | |
P/B ratio |
3.47 | 5.91 | 4.39 | 8.04 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.91 | 1.03 | 0.94 | 1.42 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.68) | (12.23) | (14.07) | (27.46) | |
EV/FCF |
(6.43) | (11.55) | (12.92) | (24.72) | |
Quick Ratio |
1.68 | 1.25 | 1.46 | 1.05 | |
Current Ratio |
2.02 | 1.67 | 1.88 | 2.01 | |
Net Debt/EBITDA |
(7.35) | (5.10) | (47.07) | 26.22 | |
Debt/Assets |
46.49% | 48.87% | 46.77% | 46.80% | |
Debt/Equity |
2.51 | 3.59 | 2.84 | 2.76 | |
Asset Turnover |
1.06 | 1.13 | 1.17 | 1.15 | |
Operating CF/Net income |
(0.13) | 0.87 | 0.29 | (0.73) | |
Capex/Depreciation |
(0.28) | (0.23) | (0.57) | 0.00 | |
Interest Coverage |
(2.18) | (3.97) | (0.71) | 0.25 | |
Research and Development Expense of Revenue |
3.99% | 3.96% | 3.21% | 2.84% | |
Selling, General and Administrative Expense of Revenue |
60.04% | 69.03% | 51.45% | 48.04% | |
Intangible Assets out of Total Assets |
0.30 | 0.33 | 0.31 | 0.31 | |
Share Based Compensation of Revenue |
5.22% | 4.87% | 1.66% | 0.42% | |
Graham Net Nets |
(0.59) | (0.61) | (0.60) | (0.31) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(42.75%) | (37.24%) | (33.85%) | (14.10%) | |
Free Cash Flow Yield |
(23.27%) | (13.43%) | (11.81%) | (5.11%) | |
Revenue per Share |
0.63 | 0.50 | 0.57 | 0.54 | |
Operating CF per Share |
0.01 | (0.14) | (0.01) | 0.02 | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
0.01 | (0.14) | (0.02) | 0.02 | |
Cash per Share |
0.52 | 0.28 | 0.34 | 0.37 | |
Shareholders Equity per Share |
0.40 | 0.25 | 0.30 | 0.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.40 | 0.25 | 0.30 | 0.29 | |
Free Cash Flow |
0.69 | (9.59) | (1.42) | 1.24 | |
Working Capital |
31.03 | 18.89 | 24.92 | 27.03 | |
Capital Expenditures |
(0.22) | (0.17) | (0.42) | — | |
Net Current Asset Value |
(53.76) | (61.20) | (56.66) | (55.67) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
20.59 | 21.55 | 21.46 | — | |
Average Payables |
10.91 | 9.96 | 11.07 | 10.77 | |
Average Inventory |
4.29 | 4.39 | 5.22 | 4.63 | |
Average Assets |
141.23 | 133.71 | 133.09 | 138.71 | |
Average Common Equity |
29.02 | 28.30 | 26.57 | 26.88 |
Columns are period end dates · fundamentals updated 4 Nov 2026